Djibouti vs Maldives: Access to anti-retroviral drugs, female
Djibouti
23.0%
in 2024
Maldives
21.0%
in 2024
Djibouti rank
137th
Maldives rank
138th
Access to anti-retroviral drugs, female over time
- Djibouti
- Maldives
How they compare
Djibouti currently reports 23.0% against 21.0% in Maldives, a difference of 2.0%.
That makes Djibouti's figure about 1.1 times Maldives's.
The two have swapped places 5 times across 24 shared years of data; in 2000 it was Maldives ahead.
Djibouti ranks 137th and Maldives ranks 138th of 141 countries.
Across the 3 decades both report, Djibouti averaged higher in 2 and Maldives in 1.
Head to head by decade
| Decade | Djibouti | Maldives | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 2.8% | 9.7% | 6.9% | Maldives |
| 2010s | 17.7% | 8.4% | 9.3% | Djibouti |
| 2020s | 23.8% | 20.2% | 3.6% | Djibouti |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Djibouti or Maldives?
- Djibouti, at 23.0% against 21.0% in Maldives as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Djibouti and Maldives?
- 2.0%, with Djibouti ahead.
- How many years of comparable data are there for Djibouti and Maldives?
- 24 years are reported by both, from 2000 to 2024.
- How do Djibouti and Maldives rank globally for access to anti-retroviral drugs, female?
- Djibouti ranks 137th and Maldives ranks 138th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.